Introduction
Diagnostic tools for prostate cancer consist of DRE, serum PSA measurements, and definite diagnosis is always based on pathological evaluation of TRUS-guided systematic biopsies (SBs). However, TRUS-guided biopsy has several limitations. As 25-39% of the prostate carcinomas are iso-echoic on grey scale TRUS, biopsies cannot be limited to lesion-directed biopsies and therefore SBs have to be taken [1, 2] . Limitations of SB include the low negative predictive value (NPV) and poor correlation with pathology results after radical prostatectomy (RP) [3] .
To overcome these problems, in the last decade, the focus has been on developing more accurate imaging methods for taking targeted biopsies (TBs). Research has been focused on multiparametric MRI (mpMRI), elastography, dynamic contrast-enhanced ultrasonography (DCEUS), histoscanning, and artificial neuronal network analysis (ANNA)/ computerised TRUS (C-TRUS ). In general, mpMRI includes two or three MRI modalities: T2-weighted imaging , diffusion-weighted imaging (DWI), and in most cases dynamic contrast-enhancement MRI (DCE-MRI), and sometimes four, adding MR-spectroscopy. mpMRI has been reported to have a high accuracy for the detection of prostate cancer [4] , and has already been recommended for patients with a persistent clinical suspicion of prostate cancer after prior negative biopsies in the European Society of Urogenital Radiology (ESUR) prostate MR guidelines 2012 [5] and in the European Association of Urology guidelines on Prostate Cancer 2014 [6] .
TRUS is a non-invasive procedure used to guide the needle for taking prostate biopsies. Image fusion can combine advantages of both TRUS and mpMRI. Approaches of taking MRI-guided TBs of the prostate include 'in-bore' MRI-guided biopsies, cognitive fusion, and MRI/ ultrasonography (MRI/US) software-based image-fusion techniques. In in-bore MRI-guided techniques, TBs are taken during real-time MRI. With fusion techniques, MRI is performed before taking US-guided TBs, using cognitive or software-based MRI-US image fusion. A higher detection rate of clinically significant disease was assessed using any of the three techniques [7] . Recently, a comparison has been made between MRI TBs and randomised TRUS-guided SBs by Van Hove et al. [8] . They concluded that no clear advantage of TBs over the current standard of SBs could be seen in biopsy na€ ıve men, but in cases of prior negative biopsies, TBs tended to have improved prostate cancer detection rates (CDRs).
Eight fusion platforms were USA Food and Drug Administration (FDA) registered at the time this review was performed. They all require a pre-biopsy MRI for real-time TRUS fusion; however, great differences between the platforms exist. Of most importance is the difference between 'rigid' and 'elastic' registration. Often, the shape of the prostate differs significantly between MRI and TRUS imaging. Elastic methods stretch or warp one of the image datasets, so that the shapes correlate with each other. Other differences include mechanical vs manually controlled arm, patient movement compensation, and accuracy of three-dimensional modelling. To the best of our knowledge, no systematic review has been performed to compare different MRI/USfusion platforms for taking prostate TBs.
The aim of the present review was to assess the CDRs of different MRI/US-fusion platforms for prostate cancer detection by comparing MRI/US-fusion TB to random SB and to the other MRI/US-fusion techniques, in-bore and cognitive fusion-guided TB. Only well-designed and prospective randomised and non-randomised trials were included in the review.
Patients and Methods

Eligibility Criteria
Randomised and non-randomised prospective clinical trials comparing prostate CDRs between MRI/US fusion-guided TB or another way of MRI TB, such as cognitive or in-bore MR/ US-fusion, and SB were selected. Participants of any age with a clinical suspicion on prostate cancer because of high PSA level and/or abnormal DRE were considered. The primary outcome measure was (clinically significant) prostate CDRs per patient. Eligibility assessment was performed by two reviewers (M.G. and A.A.). Disagreements were resolved by consensus. All abstracts published before January 2004 were excluded, as in this year the first MRI/US-fusion platform was FDA registered. Articles only including patients on active surveillance were also excluded, because the objective was to assess CDRs for prostate cancer diagnosis.
Study Selection
Data Extraction
One review author (M.G.) extracted the following data: type of fusion platform, number and type of patients, method, comparison, outcome measures, and results, and entered the information in a data extraction sheet. All other authors checked these data and disagreements were resolved by discussion and consensus. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool [9] was used to assess the quality of included the articles.
The primary outcome measure was the prostate CDR in MRI/US fusion platform-guided TB compared with SB or another way of MRI-guided TB, such as cognitive or inbore.
Results
Characteristics of Included Studies
In all, 2098 records were identified during the systematic literature search. After adjusting for duplicates 1865 records remained, of which 130 titles seemed relevant. Of these, 107 records were excluded because after analysing abstracts the papers did not meet the inclusion criteria. Next, the content of 23 papers were screened on relevance, and finally 11 studies met all our inclusion criteria. A flowchart of study selection is provided in Figure 1 . All 11 studies finally selected were prospective non-randomised controlled trials or in-patient control studies published in English between January 2004 and February 2015. Of the 11 included studies, there were eight studies comparing transrectal MRI/USfusion TBs with SBs and three studies comparing transperineal MRI/US-fusion TBs with SBs. Unfortunately, no study comparing MRI/US-fusion TB with in-bore TB, was detected.
Participants
The included studies involved 2626 patients: 1119 biopsy na€ ıve men, 1433 after prior negative biopsy, 50 not mentioned (either biopsy na€ ıve or after prior negative biopsy) and 24 on active surveillance. Despite active surveillance being an exclusion criterion, one study including 125 patients of whom 24 patients were on active surveillance was included in the present review, because the authors presented a separate analysis for the active surveillance group, so that these men could be disregarded. Table 1 shows the characteristics of the 11 included studies. For the intervention, a pre-biopsy 1.5 T or 3.0 T mpMRI including at least T2-weighted imaging, DWI and DCE modalities, with or without endorectal coil, was used. MRI/ US-fusion TBs were performed first in eight studies, SBs were performed first in the other three studies. The physician taking SBs was 'blinded' to the MRI images in five studies. In two studies, the physician taking the SBs was not blinded to the MRI images, and in the other four studies, blinding was not mentioned.
Intervention
The mpMRI lesions were scored using the Prostate ImagingReporting And Data System (PI-RADS), Likert score or National Institutes of Health (NIH) score. MRI/US-fusion TBs were taken transrectally in eight studies and transperineally in three studies, with the mean number of cores taken ranging from 1.5 to 8.9 per patient.
Outcomes
In all studies, the primary or secondary outcome assessed was the CDR of all prostate cancer and/or the CDR of clinically significant prostate cancer. When clinically significant [20] .
Risk of Bias Within Studies
For a transparent rating of bias and applicability of diagnostic accuracy studies, the QUADAS-2 tool was used to assess the quality of included articles (Table 2) . In all studies, patient selection and index test were defined as low risk of bias. Risk of bias concerning the reference test was assessed high in all included studies because of the low accuracy of prostate SBs. Applicability of the index test was scored as a high risk of bias in all studies, because of the different fusion platforms and strategies for MRI/US fusion-guided prostate TBs. The item 'flow and timing' was assessed as high risk of bias in a few studies, because time from mpMRI until prostate TB was not mentioned.
Results of Individual Studies
The CDR of all prostate cancers and when mentioned, clinically significant prostate cancers, per patient of individual studies are presented in Table 3 . A sub-analysis with the CDRs for low-vs moderate-to high-risk lesions, graded on mpMRI is presented in Table 4 .
Syntheses of Results
In all, 11 studies were included in this systematic review, using Virtual Navigator (one study, [14] ), Urostation (three studies [14, 15, 17] ), Logiq 9 (one study [21] ), UroNav (three studies [11, 12, 18] ), Artemis (one study [13] ), BiopSee (one study [19] ) and BioJet (two studies, [10, 16] Delongchamps et al. [14] made a comparison of the accuracy of visually estimated TB (VE-TB) vs MRI/US-guided TB using a rigid (Virtual Navigator) or elastic (Urostation) approach, all compared to standard 12-core SB. In all, 391 biopsy na€ ıve men were included and divided into three groups (VE-TB, rigid fusion, elastic fusion). In conclusion, MRI/US-guided TB performed significantly better (CDRs of 79.5% and 75.6% for Virtual Navigator and Urostation, respectively) than SB (ranging from 33.1% to 45.8% in all three groups), whereas VE-TB did not (74.1%).
Fiard et al. [17] included 30 patients with a clinical suspicion of prostate cancer, 17 men with prior negative biopsy and 13 Junker et al. [21] analysed 50 patients using the Logiq 9 fusion system. The CDRs of TB and SB were 46% and 36%, resulting in a sensitivity of 69.2% for SB (18/26) and 88.5% for TB (23/26), respectively.
Kuru et al. [19] made a comparison between transrectal USguided transperineal-fusion TB, using the BiopSee platform, and transperineal SB. The CDRs of all prostate cancers were equal in both SB and TB (50.4% and 50.6% respectively). However, there was a difference in the CDR in favour of TB for clinically significant prostate cancers according to the NCCN guidelines (41.1% for TB vs 38.0% for SB).
Mozer et al. [15] included 152 biopsy na€ ıve men. The CDRs of all prostate cancers for TB and SB were 53.9% and 56.6%, respectively, but there was a statistical significant difference in the CDRs of clinically significant prostate cancer between the two protocols in favour of TB (43.3% vs 36.8%).
The value of the UroNav platform was examined by Rastinehad et al. [11] . In all, 105 patients were included in their trial. The CDRs of all prostate cancers by TB vs SB were 50.5% and 48.8%, respectively. For clinically significant disease, the CDRs were 44.8% and 32.4%, respectively, which was a statistically significant difference.
The UroNav platform was also used by Salami et al. [12] with the difference being statistically insignificant. For the 101 biopsy na€ ıve patients or with prior negative biopsy only, the total CDR was 33.7% vs 30.7% for the MRI/US-guided TBs vs VE-TBs. Pooled TBs (MRI/US-guided TB and VE-TB together) compared with SB in 67 biopsy na€ ıve men showed a lower overall CDR (40.3% vs 55.2%) and less Gleason score 6 disease (7.5% vs 22.4%), but detected an equivalent number of Gleason score ≥7 disease (32.8% vs 32.8%).
A sub-analysis was made of low-vs moderate-to high-risk lesions, graded on mpMRI.
Moderate-to high-risk lesions include 4-5 lesions on a 5-point scale and 2-3 lesions on a 3-point scale. Four studies gave an overall sub-analysis, with CDRs for low-risk lesions ranging from 24.2% to 47.5% and for moderate-to high-risk lesions from 41.6% to 83.3%.
Five studies made a sub-analysis for TB of low-vs moderateto high-risk lesions, but only two of these studies also gave a sub-analysis of SB. Within these two studies, including 245 patients, the CDRs in low-risk lesions were almost equal in TB and SB (CDRs of 26.5-32.5% in TB and 35.0-36.8% in SB) with a difference in CDRs in moderate-to high-risk lesions in favour of TB (CDRs 61.5-76.4% in TB and 56.9-59.7% in SB).
Discussion
In the present review, the value of different MRI/US platforms in prostate cancer detection was assessed by comparing the CDRs of MRI/US-fusion TBs with SB, and to other MRI/US-fusion techniques, such as in-bore and VE-TB. Most importantly, seven of eight FDA registered MRI/USfusion platforms have been validated using prospective studies comparing CDRs of MRI/US-guided TBs with VE-TBs or SBs in the diagnosis of prostate cancer.
To date, the diagnosis of prostate cancer has had substantial limitations. First of all, biopsy Gleason score upgrading after pathological assessment of RP specimens shows a discrepancy between grading in TRUS-guided SBs and RP specimens [22] . Because of this discrepancy and due to the lack of large cohort studies, a good prediction of clinically significant disease is hampered.
Secondly, there is an ongoing debate about the definition of 'clinically significant' disease and in addition, with the introduction of TB, the question arises as to whether the same definition for clinically significant prostate cancer should be maintained for cores obtained with SB and TB. To overcome over-diagnosis and overtreatment, it is important to limit the diagnosis of clinically insignificant prostate cancer. There is some evidence that the criteria for clinically significant prostate cancer suggested by Epstein et al. [23] have a high likelihood for identifying organ-confined disease but not clinically insignificant disease [24, 25] . Therefore, the most ideal development in prostate cancer diagnosis would be a test with high positive predictive values (PPVs) and NPVs for clinically significant disease. A recently published systematic review by F€ utterer et al. [26] showed NPVs and PPVs for clinically significant prostate cancer with mpMRI ranging from 63% to 98% and 34% to 68%, respectively. The overall sensitivity and specificity of mpMRI reported are promising, but the additional value of DCE-MRI is still questioned [27] . Also, of great importance is the evidence that there are statistically significant histological differences between detected and missed prostate cancers on mpMRI [28] , with detected prostate cancers on mpMRI showing more clinically significant features. The CDR in patients with prior negative biopsy with in-bore MR-guided TB varies from 52% to 59% [29, 30] . TB especially may play a role in improving anterior prostate cancer detection [31] . There are some general limitations in assessing the value of MRI/US-fusion TBs. First of all, the range in CDRs at SB suggests that there is a difference in the quality of taking biopsies. Furthermore, it seems plausible that the strength of the MRI magnet and the use of an endorectal or pelvic coils determine the quality of MR images and the experience of the radiologist and physician performing the biopsy determines the quality of the biopsy cores, which determines the CDR. However, this has not been properly studied. In most of the included studies, men with negative mpMRI were disregarded, which creates selection bias and makes the results less applicable to clinical practice. And although direct visualisation of the biopsy needle inside the suspicious area is technically possible [33] , in common practice, it is almost never used.
The present systematic review has several limitations. First of all, 11 studies met our inclusion criteria, including 2626 patients. Because of this limited number of included studies, no statement can be made about the difference in the CDRs between the different fusion platforms. Another important limitation is the lack of a general definition of clinically significant prostate cancer. As shown in our present results, in the 11 included articles, four different definitions are being used. The aim of our present systematic review was to assess the CDRs in MRI/US-fusion TB vs SB in the diagnosis of prostate cancer. Patients included in the original studies are heterogeneous, containing biopsy na€ ıve men and men with one, two or sometimes more prior negative biopsies. Because previous studies show that the CDR is dependent on biopsy session number [34, 35] , the included studies are difficult to compare. On the other hand, these results are applicable to clinical practice. A general limitation of studies using SB as a reference test is that it lacks accuracy, i.e. has low sensitivity and specificity [3] . It is used because a good gold standard, such as RP, is unethical to use.
Conclusion
Although MRI/US-fusion TB has proved its value in men with prior negative biopsies, general use of this technique in the diagnosis of prostate cancer should only be performed after critical consideration because in our present analysis, no clear advantage of MRI/US fusion-guided TB could be found for CDRs of all prostate cancers; however, MRI/US fusionguided TBs tended to give a higher CDR for clinically significant prostate cancers. Before bringing MRI/US fusionguided TB in to general practice, there is a need for more prospective studies on its effectiveness for prostate cancer diagnosis.
Parallel to our research question about CDRs, is the important question of whether SB can be omitted, because this will have an impact on clinical practice. There is also a need for more research into how many prostate cancers are missed by TB, and their clinical relevance. Moreover, individual quality of taking prostate biopsies is an underreported problem that causes bias.
